Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force

(2013) Roger Chou et al.   ANNALS OF INTERNAL MEDICINE

The impact of PLCO control arm contamination on perceived PSA screening efficacy

(2012) Roman Gulati et al.   CANCER CAUSES & CONTROL

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

(2012) G. L. Andriole et al.   JNCI-Journal of the National Cancer Institute

Prostate-Cancer Mortality at 11 Years of Follow-up

(2012) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality-of-Life Effects of Prostate-Specific Antigen Screening

(2012) Eveline A.M. Heijnsdijk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities

(2011) Naomi Williams et al.   BJU INTERNATIONAL

Screening for prostate cancer: an updated Cochrane systematic review

(2011) Dragan Ilic et al.   BJU INTERNATIONAL

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

(2011) Roman Gulati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Prostate-Cancer Screening — What the U.S. Preventive Services Task Force Left Out

(2011) Allan S. Brett et al.   NEW ENGLAND JOURNAL OF MEDICINE

One Man at a Time — Resolving the PSA Controversy

(2011) Mary F. McNaughton-Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result

(2010) R C Macefield et al.   BRITISH JOURNAL OF CANCER

Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

(2010) J.A. Lane et al.   EUROPEAN JOURNAL OF CANCER

ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences?

(2010) Fritz H. Schröder et al.   EUROPEAN UROLOGY

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

(2009) Monique J. Roobol et al.   EUROPEAN UROLOGY

Eleven-Year Outcome of Patients with Prostate Cancers Diagnosed During Screening After Initial Negative Sextant Biopsies

(2009) Fritz H. Schröder et al.   EUROPEAN UROLOGY

Screening for prostate cancer remains controversial

(2009) David E Neal et al.   LANCET

Mortality Results from a Randomized Prostate-Cancer Screening Trial

(2009) Gerald L. Andriole et al.   NEW ENGLAND JOURNAL OF MEDICINE

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?

(2008) Kerry N.L. Avery et al.   BJU INTERNATIONAL

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified

(2008) Liz Down et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial

(2007) Kerry N.L. Avery et al.   EUROPEAN UROLOGY